Caroline Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Caroline Thomas has a total of 341 co-authors. Here are the top co-authors by number of shared publications:
- Nizar Mahlaoui
French National Reference Center for Primary Immune Deficiencies, Necker Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
4 shared publications Alexandra Léger
CHU de Nantes, Service D'hématologie et D'immunologie Pédiatrique, Hôpital Mère-Enfants, France
3 shared publications- Capucine Picard
Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Imagine Institute, Paris, France
3 shared publications Isabelle Pellier
Oncology, Hematology, Immunology Pediatric Unit, Angers University Hospital, Angers, France
3 shared publicationsM. Audrain
Laboratoire d'immunologie, CHU de Nantes, 44000 Nantes, France
3 shared publications- Marie Audrain
CHU de Nantes, Nantes Université, Laboratoire d'Immunologie, CIMNA, Nantes, France
3 shared publications
Latest Publications
- 22 July 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (5) , 840-851
Eczema in inborn errors of immunity with atopy: frequency, timing and phenotypic clustering
Background: Inborn errors of immunity (IEI) with atopy (IEI-A) are a subgroup of IEIs with eczema as a prominent clinical feature that can mimic atopic dermatitis (AD). However, IEI-A-associated eczema can differ from that of classic AD, and its frequency, genotype-specific clinical patterns and temporal relationships with other manifestations of IEI-A (infections, allergic manifestations, autoimmunity) remain poorly defined. Objectives: To characterize the frequency of eczema, timing and phenotypes in patients with IEI-A, and to explore the relationship of eczema with other clinical manifestations of IEI-A. Methods: This retrospective study used data from the French National Referral Center for Primary Immunodeficiency Diseases (CEREDIH), focusing on patients with genetically defined IEI-A followed in three large CEREDIH-participating centres and available clinical data. Eczema frequency and onset in relationship to other clinical events, particularly severe-or-unusual infections, was assessed, as were eczema phenotypes, concomitant allergic manifestations, treatments and autoimmunity. Clustering analyses were computed to identify distinct IEI-A eczema-associated clinical phenotypes. Results: Among 373 patients with IEI-A, varying widely by genotype, 50.9% (n = 190) had eczema. All patients deficient in DOCK8 (dedicator of cytokinesis-8) were affected, followed by those deficient in FOXP3 (n = 22/30; 73%) and those with STAT3 loss of function (n = 44/59; 75%). Onset was usually early (median 4 months). Eczema frequency and clinical presentation varied markedly across IEI-A genotypes; four phenotypic clusters were identified, with particular localizations and severe pruritus being strongly associated with pathogenic STAT3 or DOCK8 variants. For children with isolated eczema at 24 months, the risk of developing IEI-related severe or unusual infections was lower than that of persistent isolated eczema until the age of 6.8 years. Conclusions: Eczema is a common, early feature of IEI-A, often preceding infections by years. While 38.4% (n = 73/190) of patients with IEI-A with eczema fulfilled the UK Working Party diagnostic criteria for AD, some clinical pictures may differ from that of classic AD. At a time when systemic AD treatments are rapidly advancing in paediatrics, recognizing these patterns to identify patients with IEI-A could refine diagnostic strategies, improve IEI detection among children with eczema, shorten the time to IEI-A diagnosis, guide tailored management and ensure patients receive the optimal care.
- 22 July 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (5) , 840-851
Eczema in inborn errors of immunity with atopy: frequency, timing and phenotypic clustering
Background: Inborn errors of immunity (IEI) with atopy (IEI-A) are a subgroup of IEIs with eczema as a prominent clinical feature that can mimic atopic dermatitis (AD). However, IEI-A-associated eczema can differ from that of classic AD, and its frequency, genotype-specific clinical patterns and temporal relationships with other manifestations of IEI-A (infections, allergic manifestations, autoimmunity) remain poorly defined. Objectives: To characterize the frequency of eczema, timing and phenotypes in patients with IEI-A, and to explore the relationship of eczema with other clinical manifestations of IEI-A. Methods: This retrospective study used data from the French National Referral Center for Primary Immunodeficiency Diseases (CEREDIH), focusing on patients with genetically defined IEI-A followed in three large CEREDIH-participating centres and available clinical data. Eczema frequency and onset in relationship to other clinical events, particularly severe-or-unusual infections, was assessed, as were eczema phenotypes, concomitant allergic manifestations, treatments and autoimmunity. Clustering analyses were computed to identify distinct IEI-A eczema-associated clinical phenotypes. Results: Among 373 patients with IEI-A, varying widely by genotype, 50.9% (n = 190) had eczema. All patients deficient in DOCK8 (dedicator of cytokinesis-8) were affected, followed by those deficient in FOXP3 (n = 22/30; 73%) and those with STAT3 loss of function (n = 44/59; 75%). Onset was usually early (median 4 months). Eczema frequency and clinical presentation varied markedly across IEI-A genotypes; four phenotypic clusters were identified, with particular localizations and severe pruritus being strongly associated with pathogenic STAT3 or DOCK8 variants. For children with isolated eczema at 24 months, the risk of developing IEI-related severe or unusual infections was lower than that of persistent isolated eczema until the age of 6.8 years. Conclusions: Eczema is a common, early feature of IEI-A, often preceding infections by years. While 38.4% (n = 73/190) of patients with IEI-A with eczema fulfilled the UK Working Party diagnostic criteria for AD, some clinical pictures may differ from that of classic AD. At a time when systemic AD treatments are rapidly advancing in paediatrics, recognizing these patterns to identify patients with IEI-A could refine diagnostic strategies, improve IEI detection among children with eczema, shorten the time to IEI-A diagnosis, guide tailored management and ensure patients receive the optimal care.
- 5 April 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2113-2123
Neurofilament as a biomarker of neurodegeneration in childhood Langerhans cell histiocytosis: A feasibility study on 273 patients
Summary: Neurodegeneration (ND) is a severe complication of Langerhans cell histiocytosis (LCH), often leading to progressive neurological decline. We evaluated the usefulness of using plasma and cerebrospinal fluid neurofilament light chain (p‐ and CSF‐NFL) levels as biomarkers to identify and monitor ND‐LCH. NFL levels were measured using the single‐molecule array for a subset of patients from the French National LCH Registry. NFL levels in 692 plasma and 115 CSF samples from 273 registry‐enrolled children were analysed. Based on 84 paired plasma and CSF samples from 67 patients, p‐ and CSF‐NFL levels were strongly correlated ( p < 0.0001). The areas under the receiver operating characteristics curves for ND‐LCH were 72% (95% confidence interval [CI], 64%–78%) for p‐NFL and 94% (95% CI, 88%–98%) for CSF‐NFL. The highest p‐NFL (13.7 vs. 7.2 pg/mL; z ‐score 2.3 vs. 0.6) and CSF‐NFL (436.9 vs. 65.2 pg/mL) levels were significantly higher for ND‐LCH than in no‐ND‐LCH patients, respectively ( p < 0.0001). Plasma NFL levels were not elevated at LCH diagnosis. At LCH diagnosis, p‐NFL was not predictive of ND, but it may serve as a minimally invasive screening tool for ND in LCH, although optimal timing remains to be determined.
- 5 April 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2113-2123
Neurofilament as a biomarker of neurodegeneration in childhood Langerhans cell histiocytosis: A feasibility study on 273 patients
Summary: Neurodegeneration (ND) is a severe complication of Langerhans cell histiocytosis (LCH), often leading to progressive neurological decline. We evaluated the usefulness of using plasma and cerebrospinal fluid neurofilament light chain (p‐ and CSF‐NFL) levels as biomarkers to identify and monitor ND‐LCH. NFL levels were measured using the single‐molecule array for a subset of patients from the French National LCH Registry. NFL levels in 692 plasma and 115 CSF samples from 273 registry‐enrolled children were analysed. Based on 84 paired plasma and CSF samples from 67 patients, p‐ and CSF‐NFL levels were strongly correlated ( p < 0.0001). The areas under the receiver operating characteristics curves for ND‐LCH were 72% (95% confidence interval [CI], 64%–78%) for p‐NFL and 94% (95% CI, 88%–98%) for CSF‐NFL. The highest p‐NFL (13.7 vs. 7.2 pg/mL; z ‐score 2.3 vs. 0.6) and CSF‐NFL (436.9 vs. 65.2 pg/mL) levels were significantly higher for ND‐LCH than in no‐ND‐LCH patients, respectively ( p < 0.0001). Plasma NFL levels were not elevated at LCH diagnosis. At LCH diagnosis, p‐NFL was not predictive of ND, but it may serve as a minimally invasive screening tool for ND in LCH, although optimal timing remains to be determined.
- Open Access
- 14 January 2026
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (6) , 512-519
Analysis of infectious complications in paediatric autoimmune neutropenia: a French nationwide retrospective cohort study
Background: Autoimmune neutropenia (AIN) is the main cause of chronic neutropenia in children, but its infectious consequences remain poorly studied. The primary objective of this study was to evaluate infectious events leading to emergency department or hospital admissions during the first 2 years following the diagnosis of AIN in children. Methods: We performed a retrospective, multicentre analysis of medical records from 21 French university hospitals of patients aged under 18 years diagnosed with AIN with positive antineutrophils autoantibodies. We collected data on emergency room visits and hospitalisations in the 2 years following diagnosis, causes of these events, microbiology results, management and outcome. Results: One hundred and sixty-eight patients were enrolled. Median age at diagnosis of AIN was 13 months. AIN was predominantly diagnosed during an infectious episode (n=120, 71%). In the 2 years of follow-up after diagnosis, 248 events of emergency room visits and/or hospitalisations were reported (0.77 per patient-year). The most frequent diagnoses were common childhood viral or bacterial infections. The incidence rate of severe infections was 0.003 per patient-year. Despite the predominance of viral infections, 177 episodes (71%) led to hospitalisation and 166 (68%) to the initiation of antibiotic therapy, for a median duration of 7 days (IQR 3–10). Conclusion: The risk of severe infections in children with AIN is low. During follow-up, we suggest being attentive to signs of severity during fever, particularly in children over 3 years of age and/or with other immunological comorbidities but not proposing systematic hospitalisation or additional antibiotic therapy.
- 14 January 2026
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (6) , 512-519
Open AccessAnalysis of infectious complications in paediatric autoimmune neutropenia: a French nationwide retrospective cohort study
Background: Autoimmune neutropenia (AIN) is the main cause of chronic neutropenia in children, but its infectious consequences remain poorly studied. The primary objective of this study was to evaluate infectious events leading to emergency department or hospital admissions during the first 2 years following the diagnosis of AIN in children. Methods: We performed a retrospective, multicentre analysis of medical records from 21 French university hospitals of patients aged under 18 years diagnosed with AIN with positive antineutrophils autoantibodies. We collected data on emergency room visits and hospitalisations in the 2 years following diagnosis, causes of these events, microbiology results, management and outcome. Results: One hundred and sixty-eight patients were enrolled. Median age at diagnosis of AIN was 13 months. AIN was predominantly diagnosed during an infectious episode (n=120, 71%). In the 2 years of follow-up after diagnosis, 248 events of emergency room visits and/or hospitalisations were reported (0.77 per patient-year). The most frequent diagnoses were common childhood viral or bacterial infections. The incidence rate of severe infections was 0.003 per patient-year. Despite the predominance of viral infections, 177 episodes (71%) led to hospitalisation and 166 (68%) to the initiation of antibiotic therapy, for a median duration of 7 days (IQR 3–10). Conclusion: The risk of severe infections in children with AIN is low. During follow-up, we suggest being attentive to signs of severity during fever, particularly in children over 3 years of age and/or with other immunological comorbidities but not proposing systematic hospitalisation or additional antibiotic therapy.
- 5 November 2025
- Published by Elsevier in Archives de Pédiatrie
- Vol. 32 (8) , 570-574
NEOSKID study: Four years of experience in newborn screening for severe combined immunodeficiencies in the Pays de la Loire region of France
- 5 November 2025
- Published by Elsevier in Archives de Pédiatrie
- Vol. 32 (8) , 570-574
NEOSKID study: Four years of experience in newborn screening for severe combined immunodeficiencies in the Pays de la Loire region of France
- Open Access
- 13 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (37) , eado5545
A pleiotropic recurrent dominant ITPR3 variant causes a complex multisystemic disease
Inositol 1,4,5-trisphosphate (IP3) receptor type 1 ( ITPR1 ), 2 ( ITPR2 ), and 3 ( ITPR3 ) encode the IP3 receptor (IP3R), a key player in intracellular calcium release. In four unrelated patients, we report that an identical ITPR3 de novo variant—NM_002224.3:c.7570C>T, p.Arg2524Cys—causes, through a dominant-negative effect, a complex multisystemic disorder with immunodeficiency. This leads to defective calcium homeostasis, mitochondrial malfunction, CD4 + lymphopenia, a quasi-absence of naïve CD4 + and CD8 + cells, an increase in memory cells, and a distinct TCR repertoire. The calcium defect was recapitulated in Jurkat knock-in. Site-directed mutagenesis displayed the exquisite sensitivity of Arg 2524 to any amino acid change. Despite the fact that all patients had severe immunodeficiency, they also displayed variable multisystemic involvements, including ectodermal dysplasia, Charcot-Marie-Tooth disease, short stature, and bone marrow failure. In conclusion, unlike previously reported ITPR1-3 deficiencies leading to narrow, mainly neurological phenotypes, a recurrent dominant ITPR3 variant leads to a multisystemic disease, defining a unique role for IP3R3 in the tetrameric IP3R complex.
- 13 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (37) , eado5545
Open AccessA pleiotropic recurrent dominant ITPR3 variant causes a complex multisystemic disease
Inositol 1,4,5-trisphosphate (IP3) receptor type 1 ( ITPR1 ), 2 ( ITPR2 ), and 3 ( ITPR3 ) encode the IP3 receptor (IP3R), a key player in intracellular calcium release. In four unrelated patients, we report that an identical ITPR3 de novo variant—NM_002224.3:c.7570C>T, p.Arg2524Cys—causes, through a dominant-negative effect, a complex multisystemic disorder with immunodeficiency. This leads to defective calcium homeostasis, mitochondrial malfunction, CD4 + lymphopenia, a quasi-absence of naïve CD4 + and CD8 + cells, an increase in memory cells, and a distinct TCR repertoire. The calcium defect was recapitulated in Jurkat knock-in. Site-directed mutagenesis displayed the exquisite sensitivity of Arg 2524 to any amino acid change. Despite the fact that all patients had severe immunodeficiency, they also displayed variable multisystemic involvements, including ectodermal dysplasia, Charcot-Marie-Tooth disease, short stature, and bone marrow failure. In conclusion, unlike previously reported ITPR1-3 deficiencies leading to narrow, mainly neurological phenotypes, a recurrent dominant ITPR3 variant leads to a multisystemic disease, defining a unique role for IP3R3 in the tetrameric IP3R complex.
- 19 April 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (9) , e30353
Pediatric post‐transplant lymphoproliferative disorder: Do not overlook digestive involvement
- 19 April 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (9) , e30353
Pediatric post‐transplant lymphoproliferative disorder: Do not overlook digestive involvement
- Open Access
- 30 September 2021
- Published by Wiley in American Journal of Hematology
- Vol. 97 (4) , 508-509
Hemophagocytic lymphohistiocytosis, what about hair?
- 30 September 2021
- Published by Wiley in American Journal of Hematology
- Vol. 97 (4) , 508-509
Open AccessHemophagocytic lymphohistiocytosis, what about hair?
- Open Access
Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
Within the International Registry of Childhood Chronic Myeloid Leukemia (CML), we identified 18 patients less than 18 years old at diagnosis of CML who were in the chronic phase and exhibiting a sustained deep molecular response (DMR) to imatinib defined as BCR-ABL1/ABL1 < 0.01% (MR4) for at least two years followed by discontinuation of imatinib. Before discontinuation, the median duration of imatinib was 73.2 months (range, 32–109) and the median duration of MR4 was 46.2 months (range, 23.9–98.6). Seven patients experienced loss of major molecular response (MMR) 4.1 months (range, 1.9–6.4) after stopping and so restarted imatinib. The median molecular follow-up after discontinuation was 51 months (range, 6–100) for the nine patients without molecular relapse. The molecular free remission rate was 61% (95% CI, 38–83%), 56% (95% CI, 33–79%) and 56% (95% CI, 33–79%) at 6, 12 and 36 months, respectively. Six of the seven children who experienced molecular relapse after discontinuation regained DMR (median, 4.7 months; range, 2.5–18) after restarting imatinib. No withdrawal syndrome was observed. In univariate analysis, age, sex, Sokal and ELTS scores, imatinib treatment and DMR durations before discontinuation had no influence on treatment free remission. These data suggest that imatinib can be safely discontinued in children with sustained MR4 for at least two years.
Open AccessDiscontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
Within the International Registry of Childhood Chronic Myeloid Leukemia (CML), we identified 18 patients less than 18 years old at diagnosis of CML who were in the chronic phase and exhibiting a sustained deep molecular response (DMR) to imatinib defined as BCR-ABL1/ABL1 < 0.01% (MR4) for at least two years followed by discontinuation of imatinib. Before discontinuation, the median duration of imatinib was 73.2 months (range, 32–109) and the median duration of MR4 was 46.2 months (range, 23.9–98.6). Seven patients experienced loss of major molecular response (MMR) 4.1 months (range, 1.9–6.4) after stopping and so restarted imatinib. The median molecular follow-up after discontinuation was 51 months (range, 6–100) for the nine patients without molecular relapse. The molecular free remission rate was 61% (95% CI, 38–83%), 56% (95% CI, 33–79%) and 56% (95% CI, 33–79%) at 6, 12 and 36 months, respectively. Six of the seven children who experienced molecular relapse after discontinuation regained DMR (median, 4.7 months; range, 2.5–18) after restarting imatinib. No withdrawal syndrome was observed. In univariate analysis, age, sex, Sokal and ELTS scores, imatinib treatment and DMR durations before discontinuation had no influence on treatment free remission. These data suggest that imatinib can be safely discontinued in children with sustained MR4 for at least two years.
- Open Access
- 12 July 2021
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 7 (3) , 42
Neonatal Screening for SCID: The French Experience
After it was demonstrated in 2005 that T cell receptor excision circle (TREC) quantification for dried blood spot (DBS) samples on Guthrie cards is an effective means of SCID screening and following several pilot studies, the practice was formally recommended in the US in 2010. More and more countries have adopted it since then. In France, before the health authorities could recommend adding SCID to the list of five diseases that were routinely screened for, feasibility and cost-effectiveness studies had to be conducted with a sufficiently large cohort of neonates. We carried out three such studies: The first sought to verify the effectiveness of the assay. The second, DEPISTREC, evaluated the feasibility of universal SCID screening in France and assessed the clinical benefit and economic advantage it would provide. Through the third study, NeoSKID, still under way and to continue until recommendations are issued, we have been offering SCID screening in the Pays de la Loire region of France. This review briefly describes routine newborn screening (NBS) and management of primary immunodeficiency diseases (PIDs) in France, and then considers the lessons from our studies and the status of SCID screening implementation within the country.
- 12 July 2021
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 7 (3) , 42
Open AccessNeonatal Screening for SCID: The French Experience
After it was demonstrated in 2005 that T cell receptor excision circle (TREC) quantification for dried blood spot (DBS) samples on Guthrie cards is an effective means of SCID screening and following several pilot studies, the practice was formally recommended in the US in 2010. More and more countries have adopted it since then. In France, before the health authorities could recommend adding SCID to the list of five diseases that were routinely screened for, feasibility and cost-effectiveness studies had to be conducted with a sufficiently large cohort of neonates. We carried out three such studies: The first sought to verify the effectiveness of the assay. The second, DEPISTREC, evaluated the feasibility of universal SCID screening in France and assessed the clinical benefit and economic advantage it would provide. Through the third study, NeoSKID, still under way and to continue until recommendations are issued, we have been offering SCID screening in the Pays de la Loire region of France. This review briefly describes routine newborn screening (NBS) and management of primary immunodeficiency diseases (PIDs) in France, and then considers the lessons from our studies and the status of SCID screening implementation within the country.
- 1 April 2021
- Published by Elsevier in The Journal of Pediatrics
- Vol. 231, 223-230
Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation
- 1 April 2021
- Published by Elsevier in The Journal of Pediatrics
- Vol. 231, 223-230
Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation